Premium
Clinical profiles and long‐term outcomes of patients with pancreatic ductal adenocarcinoma and diabetes mellitus
Author(s) -
Ben Qiwen,
Xu Maojin,
Jiang Ying,
Yuan Yaozong,
Wang Kaixuan,
Fang Jun,
Li Zhaoshen
Publication year - 2012
Publication title -
diabetes/metabolism research and reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.307
H-Index - 110
eISSN - 1520-7560
pISSN - 1520-7552
DOI - 10.1002/dmrr.1284
Subject(s) - diabetes mellitus , medicine , body mass index , type 2 diabetes mellitus , pancreatic ductal adenocarcinoma , pancreatic cancer , endocrinology , cancer
Background Diabetes mellitus (DM) is considered to be a possible risk factor and/or a manifestation of pancreatic ductal adenocarcinoma (PDAC). This study is aimed at analysing the potential association of diabetes mellitus with the development and pathogenic degrees of PDAC and post‐surgical survival of Chinese Han PDAC patients. Methods A total of 1123 patients with PDAC were recruited and included 256 patients with diabetes mellitus within 2 years (new‐onset) and 62 patients with diabetes mellitus ≥ 2 years (long‐standing). Additional 466 patients with type 2 diabetes mellitus were included in this study. Their clinical characteristics and long‐term outcomes were analysed. Results In comparison with patients with type 2 diabetes mellitus alone, PDAC patients with new‐onset diabetes mellitus had an older onset age of diabetes mellitus and lower body mass index (BMI). Among PDAC cases, patients with new‐onset diabetes mellitus were associated with neural invasion, poor tumour differentiation and shorter post‐surgical survival. However, more than half of these patients became euglycemic after surgical resection of tumours. Conclusions PDAC patients developed new‐onset diabetes mellitus at an older age, and they had shorter post‐surgical survival. The underlying mechanisms by which comorbid diabetes mellitus affect the clinical profiles and outcomes of PDAC patients deserve further researches. Copyright © 2011 John Wiley & Sons, Ltd.